Pipeline
From last resort to first choice.
Our lead program makes CAR-T safe enough for autoimmune disease, so it can reach far more people.
Our programs
Cancer. Autoimmune. Neurodegeneration.
Autoimmune diseaseLead program
Oncology
Neurodegeneration
We will name indications as programs advance.
Autoimmune disease needs a safer CAR-T.
CAR-T has put people with lupus into drug-free remission. Millions more live with autoimmune diseases it could treat.
But a treatment for a chronic disease has to be far safer than a last-resort cancer therapy. That is the bar we design for, from the very first cell.
Blood cancer
- Patients
- Often out of other options
- Risk they can accept
- High
- The therapy must be
- Worth the risk, as a last resort
Autoimmune disease
- Patients
- Living with a chronic disease
- Risk they can accept
- Low
- The therapy must be
- Safe enough to give early
Partnering
Your CAR designs, tested before the clinic.
Send us your designs. We read how each one behaves inside living cells and tell you which to take forward. Your data stays yours.
Compare designs
Hinges, linkers and signaling domains, side by side.
Flag toxicity risk
Spot signaling linked to toxicity before the clinic.
Choose your lead
Pick your best candidate with data.
Check every batch
Make sure every lot signals the same way.